Amphista Therapeutics

Amphista Therapeutics is a private, pre-clinical stage biotech developing a novel class of targeted protein degraders called Targeted Glues®. Its platform utilizes a chemistry-first approach to create molecules with superior drug-like properties, including oral bioavailability and inherent brain penetrance, enabling targeting of a wider range of tissues and indications than traditional TPD methods. The company's lead programs target BRD9 for Acute Myeloid Leukemia and SMARCA2 for Non-Small Cell Lung Cancer, with the goal of addressing high unmet medical need. Amphista's multidisciplinary team, based in the UK's 'golden triangle,' combines deep TPD expertise with computational and AI-driven approaches to advance its pipeline.

Proprietary 'Targeted Glues®' platform for next-generation targeted protein degradation (TPD). Utilizes novel, patented AMPX warheads that act as molecular glues, recruiting E3 ligases independent of cereblon/VHL. Designed for superior drug-like properties, oral bioavailability, and inherent brain penetrance.

Amphista competes in the targeted protein degradation field against first-generation PROTAC leaders like Arvinas and Kymera Therapeutics, as well as other biotechs exploring molecular glues and novel E3 ligases. Its key differentiator is the claimed superior drug-like properties and tissue reach of its degraders, designed to overcome limitations of earlier technologies.